Nick Naclerio

Tackling a global health threat like antimicrobial resistance is not for the faint of heart, but the experienced and innovative team at Pattern Bioscience is on a mission to do it. Each year, drug-resistant bacterial infections claim more than a million lives globally and cost our healthcare system billions of dollars. Traditional diagnostic methods for bacterial infections remain rooted in slow, cumbersome, decades-old technology that contributes to sub-optimal treatment and the misuse of broad-spectrum antibiotics. The Pattern system is different. We’re developing the world’s only culture-free, rapid diagnostic technology that will reduce the time needed for pathogen identification (ID) and antibiotic susceptibility test (AST) results from days to hours. Our technology combines single-cell analysis of microorganisms with machine learning tools to deliver fast, clinically actionable information. The result? Patients get the right treatment faster, to save lives, prevent side effects and reduce healthcare costs.

Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains 200+ important markers related to immune and inflammatory diseases and will run on our ARGO™ System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data.

LetsGetChecked is a global healthcare solutions company that provides the tools to manage health from home through health testing, genetic sequencing, virtual care and medication delivery for a wide range of health conditions. LetsGetCheckeds end-to-end model includes manufacturing, logistics, lab analysis, physician support, and prescription fulfillment. Founded in 2015, the company empowers people with accessible health information and care to live longer, happier lives. LetsGetChecked is available nationwide in the United States, the United Kingdom, and most EU countries. It is co-headquartered in Dublin and New York.

At Cradle Genomics, our mission is to provide knowledge that helps every pregnancy. We're dedicated to the transformation of non-invasive prenatal testing (NIPT) by offering the most comprehensive fetal genetic analysis and pregnancy health screening solutions at the earliest stages of pregnancy. Cradle Genomics is newly formed with our headquarters based in San Diego. Cradle tests are based on the genetic analysis of fetal cells quickly collected during a first trimester visit with no risk to the mother or developing fetus. We are passionate about improving patient care and enabling global access to the best possible prenatal solutions. For additional information please contact us at info@cradlegenomics.com.

DNA Script was created to revolutionize DNA synthesis with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAX™️, the world’s first benchtop DNA printer powered by enzymatic technology. With continued advancement and innovation, we believe DNA Script’s enzymatic DNA synthesis technology is poised to become the engine of genomics research and personalized medicine.

Biota is commercializing Biosurveillance for energy and industrial customers. We unlock the use of ever present microbes as sensors and tracers. Through our Biosurveillance Platform, Biota is able to extract this valuable data source, digitize it, and fill critical data gaps that other data sources are unable to provide. Our Biosurveillance Platform provides a non invasive, cost effective, 4D diagnostic that characterizes industrial environments and tracks the movement of both surface and subsurface fluids. Current and emerging applications cover energy, decarbonization, environmental monitoring, as well as industrial asset integrity.

Our vision is a world where genomic information is fully accessible, understandable and integrated into health and well being. As a leading telegenetics care delivery company, we make genetic care accessible and actionable for patients throughout the U.S. and Canada through seven-day a week access to genetic services. By partnering with health systems, providers, labs and biopharmaceutical companies, we expand the reach and impact of genomic medicine. We help our partners deliver clinical risk assessments for patients, genetic test recommendations and ordering, pre- and post-test genetic counseling through our team of expert genetic counselors, and personalized care plans. Our advisory services team uses an evidence-based approach to help partners evaluate and develop scalable, efficient and successful genetics programs.

Serimmune is an immune intelligence company that provides a holistic view of immunity to identify environmental factors in disease and health. The unique information we provide fuels development of new diagnostics, vaccines, and therapeutics. Founded in 2014, and backed by investors including Illumina Ventures, LabCorp, and Merck, Serimmune is developing new approaches for preventing, diagnosing, and treating a range of diseases.

We are guided by the vision that "everyone deserves a healthy start." Our team develops and commercializes products and services that enable early disease detection and comprehensive diagnosis. Baebies' products are powered by digital microfluidics (DMF), an innovative technology to electronically manipulate microliter-sized drops of liquid. We miniaturize conventional diagnostic testing to enable faster results using smaller sample sizes. Our testing platforms provide the answers you need while decreasing potential harm experienced from frequent invasive testing on the most vulnerable patients. Over 12 million tests delivered, and counting. Every test is a chance to save a life.

Twist Bioscience is a synthetic biology company based in South San Francisco, California. The company has developed a proprietary silicon-based manufacturing process for the production of synthetic DNA. Twist Bioscience serves Life Science researchers who are changing the world for the better. Coming from diverse fields of medicine, agriculture, and industrial chemicals, scientists use our synthetic genes, oligo pools, biopharma services, and NGS target enrichment to better lives and improve the sustainability of the planet. Twist Bioscience is uniquely positioned to help accelerate these efforts by providing precision at a scale that is otherwise unavailable. Our technology overcomes inefficiencies and enables cost-effective, rapid, precise, high-throughput DNA synthesis and sequencing. We offer both the quality and quantity researchers need now to rapidly realize opportunities ahead. Twitter @TwistBioscience Facebook facebook.com/TwistBioscience YouTube youtube.com/TwistBioscience #WeMakeDNA

23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. 23andMe was named as one of the San Francisco Chronicles Top Workplaces and one of Comparablys Best Places to Work in 2022. CEO, Anne Wojcicki was also named one of Glassdoor’s top CEOs in 2019 and one of Comparably’s "Best CEOs for Women" in 2021 and 2022. More information is available at www.23andMe.com.

At Boreal, we are committed to improving cancer patient care through development of research tools and diagnostic tests based on monitoring of circulating tumor DNA in plasma. Boreal’s OnTarget™ platform performs highly sensitive mutation detection to enable accurate tumor profiling and real-time monitoring of tumor evolution from cell-free DNA in plasma. The OnTarget™ assay is available as a research-use service to reveal tumor mutations that are undetectable with other methods and may help guide selection of therapy, improve clinical trial efficiency, and accelerate drug development programs.

Orchid Cellmark has been a leader in the genetic testing field for almost 30 years. Our results come with the guarantee of quality and are delivered with speed, convenience, and most importantly, accuracy—inclusions usually result in 99.99% or 0% probability. Whether you just need to know, or will need results that can be used in a legal matter, Orchid Cellmark should be your first step in this journey. Ordering an Orchid Cellmark DNA paternity test can be done easily online at www.orchidcellmark.com or with one phone call to 800-DNA-TEST (362-8378). Our knowledgeable representatives are ready to answer your questions over the phone or via live-chat on our website.

Genometrix Genomics Incorporated is an information technology and services company based out of 2700 Research Forest Dr, Spring, Texas, United States.

SUNY Poly SEMATECH provides a platform for partners and collaborators to foster innovation in nanotechnology research and development.

Tackling a global health threat like antimicrobial resistance is not for the faint of heart, but the experienced and innovative team at Pattern Bioscience is on a mission to do it. Each year, drug-resistant bacterial infections claim more than a million lives globally and cost our healthcare system billions of dollars. Traditional diagnostic methods for bacterial infections remain rooted in slow, cumbersome, decades-old technology that contributes to sub-optimal treatment and the misuse of broad-spectrum antibiotics. The Pattern system is different. We’re developing the world’s only culture-free, rapid diagnostic technology that will reduce the time needed for pathogen identification (ID) and antibiotic susceptibility test (AST) results from days to hours. Our technology combines single-cell analysis of microorganisms with machine learning tools to deliver fast, clinically actionable information. The result? Patients get the right treatment faster, to save lives, prevent side effects and reduce healthcare costs.

Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains 200+ important markers related to immune and inflammatory diseases and will run on our ARGO™ System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data.

LetsGetChecked is a global healthcare solutions company that provides the tools to manage health from home through health testing, genetic sequencing, virtual care and medication delivery for a wide range of health conditions. LetsGetCheckeds end-to-end model includes manufacturing, logistics, lab analysis, physician support, and prescription fulfillment. Founded in 2015, the company empowers people with accessible health information and care to live longer, happier lives. LetsGetChecked is available nationwide in the United States, the United Kingdom, and most EU countries. It is co-headquartered in Dublin and New York.

At Cradle Genomics, our mission is to provide knowledge that helps every pregnancy. We're dedicated to the transformation of non-invasive prenatal testing (NIPT) by offering the most comprehensive fetal genetic analysis and pregnancy health screening solutions at the earliest stages of pregnancy. Cradle Genomics is newly formed with our headquarters based in San Diego. Cradle tests are based on the genetic analysis of fetal cells quickly collected during a first trimester visit with no risk to the mother or developing fetus. We are passionate about improving patient care and enabling global access to the best possible prenatal solutions. For additional information please contact us at info@cradlegenomics.com.

DNA Script was created to revolutionize DNA synthesis with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAX™️, the world’s first benchtop DNA printer powered by enzymatic technology. With continued advancement and innovation, we believe DNA Script’s enzymatic DNA synthesis technology is poised to become the engine of genomics research and personalized medicine.